10 clinical trials to watch in the first half of 2022
Bio Pharma Dive
JANUARY 2, 2022
Biotech stocks ended 2021 in a slump. But positive results from eagerly anticipated studies in breast cancer, schizophrenia and Alzheimer's disease could help turn the sector's fortunes around.
Let's personalize your content